Considerations for a State Health Insurer Fee Following Repeal of the Federal 9010 Fee

Jason Levitis
John-Pierre Cardenas
Steven Costantino

STATE Health & Value STRATEGIES
Driving Innovation Across States

A grantee of the Robert Wood Johnson Foundation
About State Health & Value Strategies

State Health and Value Strategies (SHVS) assists states in their efforts to transform health and health care by providing targeted technical assistance to state officials and agencies. The program is a grantee of the Robert Wood Johnson Foundation, led by staff at Princeton University’s Woodrow Wilson School of Public and International Affairs. The program connects states with experts and peers to undertake health care transformation initiatives. By engaging state officials, the program provides lessons learned, highlights successful strategies, and brings together states with experts in the field. Learn more at www.shvs.org.

Questions? Email Heather Howard at heatherh@Princeton.edu.

Support for this presentation was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation. This presentation is meant to provide general guidance and should be used as a reference only. It may not take into account all relevant local, state, or federal laws and is not a legal document. While we have made every attempt to ensure that the information included in this presentation is accurate and reliable, we are not responsible for any errors or omissions, or updates that may be required due to subsequent changes in laws and regulations. Neither Princeton University nor its funder, the Robert Wood Johnson Foundation, will assume any legal liability that may arise from the use of this presentation. An attorney or tax advisor should be consulted with any particular questions related to this presentation.
About Jason Levitis

Jason Levitis is principal at Levitis Strategies LLC, a healthcare consultancy focusing on the Affordable Care Act’s tax provisions and state innovation waivers. He provides technical assistance to states in partnership with State Health and Value Strategies. He’s also a nonresident fellow at the Brookings Institution and a senior fellow at Yale Law School’s Solomon Center for Health Law and Policy. He served as Counselor and ACA Implementation Lead at the U.S. Treasury Department until January 2017.
About John-Pierre Cardenas

John-Pierre Cardenas is an independent health policy adviser. He was the Director of Policy and Plan Management at the Maryland Health Benefit Exchange until November 2019. In that capacity, he oversaw the development and implementation of Maryland’s state innovation waiver to establish a reinsurance program and health reform initiatives. He provides policy advice to states seeking to expand coverage and increase affordability under the ACA framework.
Contents

✔ Background – Why Now?
✔ Design Considerations
✔ Maryland and Delaware Experiences
✔ Resources
Background – Why Now?
The recent repeal of the federal health insurer fee creates an opportunity for states to secure substantial funding to support health coverage without increasing costs on consumers or industry.

- The government spending bill enacted in December 2019 repealed the annual fee on health insurance providers under ACA section 9010, which raises nearly $20 billion per year.
- A state health insurance fee can capture this revenue, seamlessly picking up where the federal fee leaves off with little or no year-to-year impact on consumers or issuers.
- A state fee could also pick up only some of the revenue from the federal fee, providing a tax cut and associated premium reduction while still collecting substantial revenue.
Two states – Maryland and Delaware – have passed fees in response to prior suspensions of the federal fee.*

Maryland and Delaware’s fees fund state reinsurance programs. A fee could also fund other affordability measures like the premium subsidies in Massachusetts, Vermont, and (as of 2020) California, or other programs.

*This opportunity is time-limited:* a seamless transition generally requires states to enact their own fee before 2021 premiums are set in mid-2020.

Without a state fee, issuers may receive a windfall, depending on how state premiums accounted for the federal fee.

* In addition, Colorado law allows a fee to be triggered for one year if the federal fee is suspended. but only in certain circumstances. It’s not clear if it will be in place in 2021.
Design Considerations
The federal health insurer fee has a complex structure: a fixed total tax amount is allocated among issuers by their share of aggregate premiums collected (modified by certain exemptions and exclusions).

- As a result, changing any one issuer’s tax bill changes every issuer’s tax bill.

States do not need to adopt this approach.

Instead, they can collect an equivalent amount through a more typical structure, where premiums are taxed at a fixed rate.

Many states have premium taxes in place, and a new tax can likely leverage the existing administrative apparatus.
Another potential complicating feature of the federal fee is that it is non-deductible for income tax purposes.

A non-deductible fee costs income-tax-paying issuers more than the amount of the fee itself.

Sales and excise taxes are typically treated as normal business expenses and therefore deductible.

- Usually, only penalties for bad behavior are non-deductible

Again, states do not need to adopt this feature.

A state fee established under normal rules will be deductible for both federal and (if applicable) state income tax purposes.
The federal fee is broad-based but with targeted exemptions and reductions:

- Premiums < $25M threshold are exempt; premiums $25M-$50M are 50% exempt
- Issuers that (1) get 80% of revenue from Medicare, Medicaid, and CHIP and (2) are incorporated as nonprofits under state law are exempt
- Other issuers exempt from income tax under sec. 501 get a 50% premium haircut
- Medicare supplemental (Medigap) plans are exempt
- Self-insured employer plans are exempt
What’s Taxed – State Fees

• States generally cannot match the federal structure exactly:
  • States cannot tax Medicare Advantage, Part D, and FEHB plans
  • Taxes on Medicaid Managed Care Orgs. (MCOs) must be broad-based and uniform

• In addition, state taxes on MCOs are generally limited to 6% of premiums in aggregate and must otherwise comply with federal Medicaid provider assessment regulations.

• Maryland’s fee generally includes everything subject to the federal fee that it legally can; it does not adopt federal exemptions and reductions.

• Delaware’s fee is narrower, excluding MCOs and stand-alone vision & dental plans
## What’s Taxed

<table>
<thead>
<tr>
<th></th>
<th>Federal Fee</th>
<th>Maryland</th>
<th>Delaware</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indiv., group, &amp; other fully-insured</td>
<td>Included</td>
<td>Included</td>
<td>Included</td>
<td></td>
</tr>
<tr>
<td>markets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stand-alone vision, dental</td>
<td>Included</td>
<td>Included</td>
<td>Excluded</td>
<td></td>
</tr>
<tr>
<td>Medicaid MCOs</td>
<td>Excludes</td>
<td>Included</td>
<td>Excluded</td>
<td>Taxes on MCOs must be broad-based, uniform &amp; generally ≤ 6% total</td>
</tr>
<tr>
<td>profits with 80% of revenue from</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>these programs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicare Adv. &amp; Part D</td>
<td>Excluded</td>
<td>Excluded</td>
<td>Excluded</td>
<td>States may not tax</td>
</tr>
<tr>
<td>FEHB</td>
<td>Included</td>
<td>Excluded</td>
<td>Excluded</td>
<td>States may not tax</td>
</tr>
<tr>
<td>Medicare Supplemental</td>
<td>Excluded</td>
<td>Excluded</td>
<td>Excluded</td>
<td></td>
</tr>
<tr>
<td>State &amp; local gov’t entities</td>
<td>Excluded</td>
<td>Excluded</td>
<td>Excluded</td>
<td></td>
</tr>
<tr>
<td>Fixed indemn., LTC, etc.</td>
<td>Excluded</td>
<td>Excluded</td>
<td>Excluded</td>
<td></td>
</tr>
<tr>
<td>Self-insured plans</td>
<td>Excluded</td>
<td>Excluded</td>
<td>Excluded</td>
<td>ERISA constraints apply</td>
</tr>
<tr>
<td>Premiums below threshold</td>
<td>Excludes</td>
<td>Excluded</td>
<td>Excluded</td>
<td>Consider MCO rules</td>
</tr>
<tr>
<td>1st $25M and 50% of $25M-$50M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tax-exempt issuers</td>
<td>50% haircut</td>
<td>Included</td>
<td>Included</td>
<td>Consider MCO rules</td>
</tr>
</tbody>
</table>
What’s Taxed

• Considerations for states:
  • Revenue
  • Continuity with federal fee
  • Level playing field
  • Maximizing federal funds
  • Leveraging existing state administrative structure

• Potential approach:
  • As a starting point, tax entities that are subject to existing state premium tax
  • Consider adding or removing specific lines to conform to federal fee
  • MCOs is a key decision point
    • Including them increases revenue and federal funds but may reduce flexibility and continuity
    • Applying federal regulations requires a state-specific analysis
Federal fee often estimated at 2.75% to 3% of premiums
- Varies due to special rules – e.g., tax-exempt issuers
- Oliver Wyman says lower after federal corporate income tax cut

Maryland’s fee was 2.75% in 2019 to collect revenue during moratorium, then changed to 1% when it appeared federal fee would be in place.

Delaware’s fee has a trigger: 1% when federal fee is in place, 2.75% when not (so 2.75% going forward)

Representative options:
- 2.75% maximizes revenue but may increase taxes on tax-exempt firms that receive 50% haircut under federal fee
- 1% collects less revenue but avoids increase on tax-exempt firms
The federal fee will be collected for the last time in September 2020 based on 2019 premiums collected. Key timing considerations for states:

- **Continuity:**
  - For seamless transition, collect state fee for the first time in 2021 based on 2020 premiums
  - Legislation should be passed by mid-2020 so fee can be baked into 2021 premiums

- **Possible windfall:** If federal fee to be paid in 2021 was baked into 2020 premiums, issuers may receive a windfall without a new state fee
  - Incentive was to bake 2021 fee into 2020 premiums, since was it based on 2020 premiums
  - But in some states, 2020 premiums may include 2020 fee. In that case, there’s no windfall
  - Any windfall would be partially returned to consumers through MLR rebates, but three-year averaging limits responsiveness, and some issuers have a cushion

**Important:** The windfall issue is separate from continuity. Regardless of which year’s fee is reflected in which year’s premiums, continuity requires a state fee to be collected for the first time in 2021 based on 2020 premiums.
### Timeline of Existing Fees

#### Fee Payment Year (Based on Prior-Year Premiums)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal fee</td>
<td>✓</td>
<td>✗</td>
<td>✓</td>
<td>✗</td>
<td>✓</td>
<td>✗</td>
</tr>
<tr>
<td>Maryland Fee</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>2.75%</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>Delaware fee</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>1%</td>
<td>2.75%</td>
</tr>
</tbody>
</table>
• Options include:
  • Reinsurance program through Section 1332 waiver
  • Subsidy for individual market coverage (premiums and/or cost-sharing)
  • Supporting a public option or Medicaid buy-in program
  • Other programs to support coverage

• May impact reactions of issuers and other stakeholders. Consider:
  • Which issuers benefit (market segment, risk profile)
  • Which consumers benefit
  • Leveraging federal dollars
Maryland and Delaware Experiences
Maryland and Delaware Experiences

- Need for funding
- Value proposition for issuers
- Stakeholder engagement
- Key stakeholder concerns
- Legislative coalition-building
Resources
A good starting point is [Oliver Wyman’s analysis](#) of the impact of the federal fee on 2020 premiums:

- Table 10 ("Additional premiums to be paid as a result of section 9010 taxes in 2020") provides a proxy for aggregate revenue by state.
- To estimate state revenue, remove the "Medicare Advantage" and "Medicare PDP” columns given the prohibition on states taxing those lines.

For more accurate and issuer-specific information, the best source is likely rate filings, which generally show the amount of federal fee built in.

- Rate filings for some states can be found at the [SERFF Filing Access portal](#)
- [The IRS’s sec. 9010 page](#) provides issuer-specific premium data for the federal fee, but it is not broken down by state.
- [CMS’s MLR reporting files](#) include section 9010 payments, but the data appear incomplete.
Other Resources

• Section 9010
  • IRS section 9010 page, with links to regulations and other information
  • IRS FAQs on section 9010 suspensions and repeal

• Maryland fee
  • Legislative language
  • Fiscal note
  • Administrative bulletins here and here

• Delaware fee
  • Legislative language
  • Administrative bulletin

• Rules regarding state taxation of health insurance
  • MCOs: 42 CFR § 433.55; 42 CFR § 433.68
  • Medicare Advantage: 42 CFR § 422.404
  • Medicare Part D: 42 CFR § 423.440
  • FEHB: 5 USC § 8909(f)(1)
For states interested in learning more, Jason Levitis is available to provide technical assistance. In addition, experts at Manatt Health are available through SHVS to help understand the complex federal rules governing states taxes on Medicaid Managed Care Organizations (MCOs) and assist states in conducting state-specific analysis.

**Jason Levitis**  
Principal, Levitis Strategies LLC  
[jason.levitis@gmail.com](mailto:jason.levitis@gmail.com)  
203-671-2609

**John-Pierre Cardenas**  
Independent Health Policy Adviser  
[johnpierre.cardenas@gmail.com](mailto:johnpierre.cardenas@gmail.com)  
443-799-6223

**Patti Boozang**  
Senior Managing Director, Manatt Health  
[PBoozang@manatt.com](mailto:PBoozang@manatt.com)  
(212) 790-4523

**Steven Costantino**  
Director of Health Care Reform, Delaware Department of Health and Human Services  
[Steven.Costantino@delaware.gov](mailto:Steven.Costantino@delaware.gov)

**Heather Howard**  
Director, State Health and Value Strategies  
[heatherh@Princeton.edu](mailto:heatherh@Princeton.edu)  
609-258-9709  
[www.shvs.org](http://www.shvs.org)

**Dan Meuse**  
Deputy Director, State Health and Value Strategies  
[dmeuse@Princeton.edu](mailto:dmeuse@Princeton.edu)  
609-258-7389  
[www.shvs.org](http://www.shvs.org)